The receptor Mas-related G protein-coupled receptor X2 (MRGPRX2) is a crucial player in many pseudoallergic reactions by directly activating mast cells, independent of IgE antibodies. This non-immunologic pathway can trigger the release of histamine and other inflammatory mediators, leading to symptoms that mimic a true allergic reaction.
Mechanism of action
Unlike a true IgE-mediated allergy, MRGPRX2-driven pseudoallergy does not require prior sensitization. The process is initiated when various ligands directly bind to the MRGPRX2 receptor on the surface of mast cells, particularly those located in the skin.
The binding of these ligands activates G-protein signaling pathways within the cell, particularly the Gαq and Gαi pathways, leading to two primary outcomes:
Calcium mobilization: The signaling cascade increases intracellular calcium levels.
Mast cell degranulation: This rise in calcium triggers the release of inflammatory mediators stored in the mast cell granules.
The release of these mediators—including histamine, proteases like tryptase, and prostaglandins—causes pseudoallergic symptoms.
Drugs and other compounds that activate MRGPRX2
A wide array of structurally diverse compounds can act as agonists for MRGPRX2. They often share a characteristic positive charge and/or hydrophobic structure.
This low-affinity, high-dose receptor can be activated by a range of both endogenous and exogenous agents, including:
Opioids: Morphine, codeine, and certain other opioid analgesics are potent activators, causing classic pseudoallergic symptoms like itching, flushing, and angioedema.
Neuromuscular blocking drugs (NMBDs): Several NMBDs used during general anesthesia, such as atracurium and mivacurium, can trigger MRGPRX2-mediated mast cell degranulation.
Fluoroquinolone antibiotics: Ciprofloxacin, levofloxacin, and other fluoroquinolones are common culprits.
Vancomycin: This antibiotic is a classic cause of "red man syndrome," a pseudoallergic reaction characterized by a rash and flushing, which is driven by MRGPRX2 activation.
Endogenous peptides: Neuropeptides like Substance P and antimicrobial host defense peptides (e.g., LL-37) also activate MRGPRX2, contributing to chronic inflammatory conditions like atopic dermatitis and rosacea.
Clinical implications and diagnosis
Because MRGPRX2-mediated reactions can be clinically indistinguishable from IgE-mediated anaphylaxis, accurate diagnosis is vital for patient safety and management.
Lack of standard tests: Unlike IgE-mediated allergy, no standard clinical test can definitively diagnose an MRGPRX2-mediated reaction. A diagnosis is often reached by exclusion, after ruling out IgE involvement through negative allergy tests.
Risk factors: Some individuals, such as those with mastocytosis or chronic spontaneous urticaria, may be more susceptible to MRGPRX2 activation due to a higher expression of the receptor on their mast cells.
Treatment implications: For suspected MRGPRX2
Reactions can be managed by adjusting the drug concentration and rate of infusion to help prevent a reaction. For example, vancomycin-induced flushing can be mitigated by administering the medication more slowly. In contrast, treatment for a true IgE-mediated allergy would focus on avoiding the specific drug and its structural relatives.
Kiraluna
